bevacizumab-awwb vs IBI305
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
bevacizumab-awwb · MVASI
Marketed by Amgen and partners
NCT01966003 · Phase 3 · completed
This randomized, quadruple-blind, active-controlled Phase 3 trial in 642 patients with advanced non-small cell lung cancer compared the biosimilar bevacizumab-awwb with reference bevacizumab, both added to chemotherapy. Objective response rates were closely matched (39.0% vs 41.7%), and the prespecified statistical test showed the two products were clinically equivalent.
Reported efficacy
Percentage of Participants With an Objective Response (Disease assessments were performed at weeks 1, 7, 13, 19, and approximately every 9 weeks thereafter. The mean actual follow-up time from randomization was 4.7 and 5.0 months for ABP 215 and bevacizumab, respectively.): Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results). (met)
Result source: NCT01966003
IBI305
Marketed by Innovent Biologics
NCT02954172 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial with 450 enrolled participants (220 and 221 in the reported primary analysis groups). Its primary clinical endpoint, objective response rate at 18 weeks, met the prespecified equivalence criterion: 44.3% with IBI305 versus 46.4% with bevacizumab, with the 90% confidence interval for the odds ratio entirely within the 0.75–1.33 equivalence margin.
Reported efficacy
Objective Response Rate (18 weeks): Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33. (met)
Result source: NCT02954172
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | bevacizumab-awwb | IBI305 |
|---|---|---|
| PFS, median | 6.6 vs 7.9vs BevacizumabNCT01966003 | 8.4 vs 8.3vs BevacizumabNCT02954172 |
| OS, median | —Not reported | 18.0NCT02954172 |
| ORR | 39% vs 41.7%vs BevacizumabNCT01966003 | 44.3% vs 46.4%vs BevacizumabNCT02954172 |
| Duration of response, median | 5.8 vs 5.6vs BevacizumabNCT01966003 | —Not reported |
PFS, median
- bevacizumab-awwb
- 6.6 vs 7.9vs BevacizumabNCT01966003
- IBI305
- 8.4 vs 8.3vs BevacizumabNCT02954172
OS, median
- bevacizumab-awwb
- —Not reported
- IBI305
- 18.0NCT02954172
ORR
- bevacizumab-awwb
- 39% vs 41.7%vs BevacizumabNCT01966003
- IBI305
- 44.3% vs 46.4%vs BevacizumabNCT02954172
Duration of response, median
- bevacizumab-awwb
- 5.8 vs 5.6vs BevacizumabNCT01966003
- IBI305
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. bevacizumab-awwb: 3 of 4 rows · IBI305: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | bevacizumab-awwb | IBI305 |
|---|---|---|
| Dropout rate | 82.3% NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | 1.3%a NCT02954172 · Phase 3 · combination |
| Discontinued due to AEs | — NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | —a NCT02954172 · Phase 3 · combination |
| Serious AEs | 26.2% NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | 33.5%a NCT02954172 · Phase 3 · combination |
| Most frequent reported AEs | alopecia 43.2% nausea 25.3% anaemia 20.1% NCT01966003 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | a white blood cell count decreased 71.9% neutrophil count decreased 70.5% platelet count decreased 50.4% NCT02954172 · Phase 3 · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
bevacizumab-awwb
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bevacizumab-awwb's landscape · IBI305's landscape